

Special Issue

Gynecologic Cancer: From Diagnosis to Treatment

Message from the Guest Editor

In recent years, enormous progress has been achieved in the diagnosis and treatment of gynecological diseases. Transvaginal ultrasound has now attained diagnostic sensitivities that are superimposable, if not superior, to 'traditional' instrumental investigations. Furthermore, surgical and medical treatment of gynecological pathologies have evolved toward increasingly personalized medicine. The advancement of knowledge has led to the molecular characterization of gynecologic pathologies for better understanding the pathology itself, allowing targeted and personalized therapies. Finally, new research has led to increasingly less invasive surgery in both oncology and benign pathology. Despite this impressive medical advancement, many questions still remain unresolved. The weight of molecular characterization versus pathological prognostic criteria in endometrial cancer, the role of minimally invasive surgery in cervical cancer, and the role of new maintenance therapies in ovarian cancer recurrence deserve to be better understood. The purpose of this Special Issue is to provide new insights into the future frontiers of scientific research in gynecology from diagnosis to treatment.

Guest Editor

Dr. Vito Andrea Capozzi
Department of Medicine and Surgery, University Hospital of Parma,
43125 Parma, Italy

Deadline for manuscript submissions

closed (20 May 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/169846

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)